Correspondence to editorial on "Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study".

Clin Mol Hepatol · 2024 · PMC11540374 · PMID 38816178

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The phase III COSMIC-312 trial revealed a statistically significant improvement in PFS compared to sorafenib, although the OS benefit did not reach statistical significance [ 10 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.